In 2023 alone, Nordic life science companies were on track to raise nearly $2 billion, as data from Citeline shows, demonstrating a consistent growth trend in external investment over the past decade. Few other regions have matched this post-COVID investment appeal, underscoring the resilience and promise of the Nordic life sciences.
The Nordic life sciences ecosystem is characterized by early IPOs, a unique culture that attracts local investors but still has room to grow internationally. A recent survey by Nordic Innovation revealed that while 40 of 120 investors had not yet invested in Nordic health tech, 90% were open to doing so, provided they find the right opportunities. The Nordic countries, particularly Finland, are seen as prime locations for initial investments, especially in digital health and companies with B2B or SaaS business models. The potential for high returns in a forward-thinking and supportive environment makes the Nordic region a compelling choice for life science investors worldwide. Challenges remain, such as accessing quality deal flow and the capital-intensive nature of the sector. However, 67% of surveyed investors expressed interest in Nordic health tech due to the region’s strong policies, scientific excellence, and burgeoning startup scene. Most investors are looking for partnerships with experienced local investors and more technological breakthroughs to drive their investment decisions.
Key Opportunities for Investors in Nordic Life Sciences
The appeal of the Nordic life science sector extends across various domains, including biotech, medtech, diagnostics, genomics, and therapeutic development. Investors and venture capitalists (VCs) are particularly interested in early funding opportunities and seed funding for start-ups in this region. The robust ecosystem in Sweden, Denmark, Norway, Finland, and Iceland fosters a fertile ground for innovations and innovators.
Nordic life science companies are increasingly attracting VC funding and capital investments, reflecting the sector’s potential for significant returns. Pharma biotech and medtech sectors are seeing notable investments, with substantial funds being allocated to support cutting-edge research and development. Founders of these start-ups benefit from the supportive environment, access to capital, and strong collaboration networks that characterize the Nordic life science landscape.
Overall, the Nordic region continues to be a hotspot for life science investments, with its combination of innovative start-ups, strong policy support, and a thriving ecosystem. Investors looking for high-potential opportunities in biotech, medtech, and related fields will find the Nordic countries to be an exceptional destination for their capital.
Nordic and international investors at Nordic Life Science Days
Nordic Life Science Days has become the main arena for investors looking into new opportunities in this part of Europe. At this year’s event on 18-19 September in Malmö, Sweden, registered investors will be able to meet the most promising Nordic start-up companies during the Nordic Star Pitch Competition and receive one-pagers on 20 pre-selected companies.
They will also be invited to mingle with other Nordic and international investors at the exclusive Investors Private Dinner held on 17 September, as well as schedule meetings with Nordic companies using the one-on-one partnering platform. Moreover, investors will have the chance to learn about the investment landscape in the Nordics during a dedicated super session and get maximum visibility in the Nordic Life Science Industry at this main Nordic Life Science event.